NEW
YORK, Sept. 4, 2024 /PRNewswire/
-- BioAro successfully launched its presence in the UK at
the Royal Society on August 29th,
2024. BioAro's UK launch marks a significant step in the
company's mission to revolutionize precision medicine.
Leveraging advanced AI-driven genomic analysis, BioAro provides
unparalleled insights into disease mechanisms, drug responses, and
patient outcomes. This expansion enhances BioAro's global reach and
impact, enabling healthcare professionals to make informed
decisions with unprecedented speed and accuracy.
"Launching BioAro in the UK represents a major milestone in our
mission to revolutionize precision medicine. By partnering with the
Golden Helix Foundation, we aim to advance global education and
make sophisticated genomic insights accessible to healthcare
professionals worldwide. Our cutting-edge technologies empower
medical practitioners to deliver more precise, personalized care,
ultimately improving patient outcomes and advancing global
healthcare," said Dr. Anmol Kapoor,
CEO and Founder of BioAro.
During the event, BioAro announced its collaboration with the
Golden Helix Foundation. This partnership aims to advance the field
of genomics through comprehensive education and training programs,
empowering scientists and healthcare professionals worldwide.
BioAro was also honored by the Golden Helix Foundation with a
Certificate of Recognition for its outstanding contribution to
global healthcare innovation through the development of its
AI-powered software solution, PanOmiQ.
The launch event featured keynote speeches, discussions, and a
showcase of technologies. Attendees had the opportunity to engage
with industry leaders and explore the latest advancements in
precision medicine. Notable speakers included:
- Dr. Christina Mitropoulou, Managing Director and Senior
Research Scientist of the Golden Helix Foundation, highlighted the
foundation's research and educational initiatives. Established in
2003, the Golden Helix Foundation advances interdisciplinary
research and education in genomic and personalized medicine,
promoting research development and facilitating knowledge transfer
in pharmacogenomics, personalized medicine, health economics, and
bioinformatics.
- Prof. Dr. George
Patrinos, a renowned expert from the University of
Patras and recent addition to BioAro's Scientific Advisory Board,
discussed the evolving landscape of genomic medicine. He brought
extensive expertise in molecular genetics, pharmacogenomics,
bioinformatics, bioethics, and pharmaceutical biotechnology. Prof.
Patrinos has authored over 340 peer-reviewed publications, 15
textbooks, and is the editor of Molecular Diagnostics by
Elsevier/Academic Press.
- Dr. Shaikha Almazrouei,
from Abu Dhabi's Technology
Innovation Institute and Head of the UAE Stem Cell Group, presented
the latest advancements in biotechnology.
BioAro leads in AI-driven real-time genomic analysis. By
integrating personal medical histories with genomic data, BioAro
delivers comprehensive clinical reports, enabling precise and
personalized medical care. The company's flagship product, PanOmiQ,
provides seamless analysis of genomics, metagenomics, and
pharmacogenomics, making advanced genomic insights accessible to a
broader range of scientists and healthcare specialists.
The Golden Helix Foundation remains committed to promoting
education and research in genomic and precision medicine. The
foundation participates in international research projects,
clinical studies, and organizes educational courses, conferences,
and seminars worldwide, fostering a global community of scientists
and healthcare professionals dedicated to advancing the field of
genomics.
"The collaboration between the Golden Helix Foundation and
BioAro represents a monumental step forward in the field of
precision medicine. By combining our expertise in educational
initiatives with BioAro's cutting-edge genomic technologies, we are
poised to revolutionize how healthcare professionals worldwide
approach personalized medicine. This partnership not only enhances
our ability to educate and empower scientists and clinicians but
also underscores our shared commitment to improving patient
outcomes and advancing global healthcare."
BioAro and the Golden Helix Foundation look forward to
continuing their joint efforts to shape the future of precision
medicine. For more information about their initiatives, please
visit www.bioaro.com.
Media Contact:
Josh Ginsburg
212-352-3320
382674@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/royal-society-hosts-bioaros-uk-launch-in-partnership-with-golden-helix-foundation-to-enhance-genomic-medicine-education-302237633.html
SOURCE BioAro